四環醫藥(00460.HK)附屬組聯合體中選吉藥預重整投資人
四環醫藥(00460.HK)公布,其附屬隆裕弘達與其他產業及財務投資人組成聯合體,近日經吉藥控股(300108.SZ)預重整投資人遴選評審委員會依法評定,中選為吉藥控股破產重整項目的預重整投資人。
吉藥控股以醫藥大健康產業為核心,主營業務包括醫藥板塊和化工板塊。其中:醫藥板塊包括醫藥工業、醫藥商業(含藥品零售)、醫藥研發等醫藥大健康產業;化工板塊主要包括高分散白炭黑系列產品的研發、生產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.